Key points are not available for this paper at this time.
Interview with Dr. Carl June on chimeric antigen receptor therapy. (09:04)Download This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors. Toxic effects of chimeric antigen receptor therapies include cytokine release syndrome and neurologic dysfunction.
Building similarity graph...
Analyzing shared references across papers
Loading...
Carl H. June
Michel Sadelain
New England Journal of Medicine
University of Pennsylvania
Memorial Sloan Kettering Cancer Center
Kettering University
Building similarity graph...
Analyzing shared references across papers
Loading...
June et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d8d22b33ca018b39ae41ee — DOI: https://doi.org/10.1056/nejmra1706169
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: